Connexios unveils diabetes drug preclinical data

CNX-011-67, a potent and selective GPR40 agonist, is a small molecule candidate that acts on the pancreatic beta cells and enhances glucose sensitivity, insulin secretion and reduce metabolic stress.

The two-pronged impact of GPR40 activation by CNX-011-67 results in enhancing insulin content and glucose stimulated insulin secretion while reducing metabolic stress in the beta cell and consequent apoptosis.

CNX-011-67 is being developed by Connexios as an oral anti-diabetic drug therapy that can protect against beta cell decline and delay the onset or progression of disease, while providing glycemic control.